Volume 19, Issue 1 (Pajouhan Scientific Journal, Autumn 2020)                   Pajouhan Sci J 2020, 19(1): 53-61 | Back to browse issues page


XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Sabzehei M K, Tanasan A, Mohammadi Y, Taheri Talesh S, Zeinali M. Comparison of Intravenous Paracetamol versus Intravenous Ibuprofen in the Closure of Patent Ductus Arteriosus (PDA) in Preterm Infants. Pajouhan Sci J 2020; 19 (1) :53-61
URL: http://psj.umsha.ac.ir/article-1-601-en.html
1- Professor, Department of Pediatric Group, School of Medicine, Hamadan University of Medical Scinces, Hamadan, Iran
2- Modeling of Noncommunicable Diseases Research Center, Hamadan University of Medical Sciences, Hamadan, Iran
3- Assistant Student, Depatment of Pediatric Group, Hamadan University of Medical Scinses, Hamadan, Iran
4- Assistant Student, Depatment of Pediatric Group, Hamadan University of Medical Scinses, Hamadan, Iran. , parisazeinali@ymail.com
Abstract:   (2724 Views)
Background and Objective: The Patent Ductus Arteriosus (PDA) occurs in 50% of infants under 1000 g and 30% of infants less than 1500 g. Treatment failure can exacerbate respiratory distress and its complications. Acetaminophen is a new drug with fewer side effects. The present study was designed and performed to evaluate the effect of this drug and  intravenous ibuprofen on the treatment of Patent Ductus Arteriosus.
Materials and Methods: In this case-control study, 50 preterm infants who were less or equal to 14 days of age and diagnosis  of PDA by echocardiographic were included and randomly divided into two groups. The first group was treated with intravenous ibuprofen and the second group was treated with intravenous acetaminophen for three days. At the end, the necessary information, including echocardiographic findings were analyzed using SPSS software version 16.
Results: The findings of the present study showed that both ibuprofen and acetaminophen had equal effect in the closing of PDA in preterm infants.  There was no significant difference in the duration of hospitalisation between two groups (P = 0.259). Possible side effects include intra-ventricular hemorrhage, thrombocytopenia, serum creatinine greater than 1.5 mg / dl, decreased urinary volume, necrotizing enterocolitis, positive blood culture and bronchopulmonary dysplasia were not significantly different between the two groups. The only significant complication was gastrointestinal bleeding, which was almost equally prevalent in both groups.
Conclusion: Acetaminophen  such as ibuprofen is effective as the main treatment of patent ductus arteriosus (PDA) and it could be a safe alternative to ibuprofen.
Full-Text [PDF 850 kb]   (947 Downloads)    
Type of Study: Research Article | Subject: Medicine & Clinical Sciences
Received: 2020/06/27 | Accepted: 2020/09/2 | Published: 2020/09/25

References
1. Swartz EN. Is indomethacin or ibuprofen better for medical closure of the patent ductus arteriosus? Arch Dis Child. 2003; 88(12): 1134-1135.
2. Lago P, Bettiol T, Salvadori S, et al. Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: a randomized controlled trial. Eur J Pediatr. 2002; 161(4): 202-207.
3. Supapannachart S, Limrungsikul A, Khowsathit P. Oral ibuprofen and indomethacin for treatment of patent ductus arteriosus in premature infants: a randomized trial at Ramathibodi Hospital. J Med Assoc Thai. 2002; 85 Suppl 4: S1252-1258.
4. Koch J, Hensley G, Roy L, et al. Prevalence of spontaneous closure of the ductus arteriosus at a birth weight of 1000 grams or less. Pediatrics. 2006; 117(4): 1113-1121.
5. Bose CL, Laughon M. Treatment to prevent patency of the ductus arteriosus: beneficial or harmful? J Pediatr. 2006; 148(6): 713-4.
6. Bose CL, Laughon MM. Patent ductus arteriosus: lack of evidence for common treatments. Arch Dis Child Fetal Neonatal Ed. 2007; 92(6):F498-502.
7. Herrman K, Bose CL, Lewis K, Laughon M. Spontaneous closure of the patent ductus arteriosus in very low birth weight infants following discharge from the neonatal unit. Arch Dis Child Fetal Neonatal Ed. 2009; 94(1): F48-50.
8. Teixeira LS, McNamara PJ. Enhanced intensive care for the neonatal ductus arteriosus. Acta Paediatr. 2006; 95(4): 394-403.
9. Clyman RI. Mechanisms regulating the ductus arteriosus. Biol Neonate. 2006; 89(4): 330-5.
10. Hermes-DeSantis ER, Clyman RI. Patent ductus arteriosus: pathophysiology and management. J Perinatol. 2006; 26 Suppl 1: S14-8.
11. McCurnin D, Clyman RI. Effect of a patent ductus arteriosus on postprandial mesenteric perfusion in premature baboons. Pediatrics. 2008; 122(6): e1262-7.
12. Lemmers PMA, Toet MC, van Bel F. Impact of patent ductus arteriosus and subsequent therapy with indomethacin on cerebral oxygenation in preterm infants. Pediatrics. 2008; 121(1): 142-7.
13. Bose CL, Laughon M. Treatment to prevent patency of the ductus arteriosus: beneficial or harmful? J Pediatr. 2006; 148(6): 713-4.
14. Malcolm WF, Hornik C, Evans A, et al. Vocal fold paralysis following surgical ductal closure in extremely low birth weight infants: a case series of feeding and respiratory complications. J Perinatol. 2008; 28(11): 782-5.
15. Kabra N, Schmidt B, Roberts R, et al. Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants. J Pediatr. 2007; 150(3): 229-34.
16. Chorne N, Leonard C, Piecuch R, Clyman RI. Patent ductus arteriosus and its treatment as risk factors for neonatal and neurodevelopmental morbidity. Pediatrics. 2007; 119(6): 1165-74.
17. Raval MV, Laughon MM, Bose CL, Phillips JD. Patent ductus arteriosus ligation in premature infants: who really benefits, and at what cost? J Pediatr Surg. 2007; 42(1): 69-75.
18. Clyman RI, Chorne N. Patent Ductus Arteriosus: Evidence for and against treatment. J Pediatr. 2007; 150(3): 216-9.
19. Chang LY, McCurnin D, Yoder B, et al. Ductus arteriosus ligation and alveolar growth in preterm baboons with a patent ductus arteriosus. Pediatr Res. 2008; 63(3): 299-302.
20. Van Overmeire B, Smets K, Lecoutere D. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. N Engl J Med. 2000; 343(10): 674-81.
21. Thomas RL, Parker GC, Van Overmeire B, Aranda J. A meta-analysis of ibuprofen versus indomethacin for closure of patent ductus arteriosus. Eur J Pediatr. 2005; 164(3): 135-40.
22. Desfrere L, Zohar S, Morville P, et al. Dose-finding study of ibuprofen in patent ductus arteriosus using the continual reassessment method. J Clin Pharm Ther. 2005; 30(2): 121-32.
23. Jegatheesan P, Ianus V, Buchh B, et al. Increased indomethacin dosing for persistent patent ductus arteriosus in preterm infants: a multicenter, randomized, controlled trial. J Pediatr. 2008; 153(2): 183-9.
24. Weiss H, Cooper B, Brook M, et al. Factors determining reopening of the ductus arteriosus after successful clinical closure with indome-thacin. J Pediatr. 1995; 127(3): 466-71.
25. Shaffer CL, Gal P, Ransom JL, et al. Effect of age and birth weight on indomethacin pharmacodynamics in neonates treated for patent ductus arteriosus. Crit Care Med. 2002; 30(2): 343-8.
26. Hammerman C, Bin-Nun A, Markowitz E, et al. Ductal closure with paracetamol: a surprising new approach to patent ductus arteriosus treatment. Pediatrics. 2011; 128(6): e1618-21.
27. Dang D, Wang D, Zhang C, Zhou W, Zhou Q, Wu H. Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial. PLoS One. 2013; 8(11): e77888.
28. Erdeve O, Yurttutan S, Altug N, Ozdemir R, Gokmen T, Dilmen U, et al. Oral versus intravenous ibuprofen for patent ductus arteriosus closure: a randomised controlled trial in extremely low birthweight infants. Arch Dis Child Fetal Neonatal Ed. 2012; 97(4): F279-83.
29. Hossain J, Shabuj MK. Oral paracetamol versus intravenous paracetamol in the closure of patent ductus arteriosus: A proportion meta-analysis. J Clin Neonatol 2018;7:121-4
30. Terrin G, Conte F, Scipione A, Bacchio E, Conti MG, Ferro R, et al. Efficacy of paracetamol for the treatment of patent ductus arteriosus in preterm neonates. Ital J Pediatr. 2014; 40(1): 21.
31. Yurttutan S, Oncel MY, Arayici S, Uras N, Altug N, Erdeve O, et al. A different first-choice drug in the medical management of patent ductus arteriosus: oral paracetamol. J Matern Fetal Neonatal Med. 2013; 26(8): 825-7.
32. Dang D, Wang D, Zhang C, Zhou W, Zhou Q, Wu H. Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial. PLoS One. 2013; 8(11): e77888.
33. Oncel MY, Yurttutan S, Erdeve O, Uras N, Altug N, Oguz SS, et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. J Pediatr. 2014;164(3):510–4 e1.
34. Sinha R, Negi V, Dalal SS. An Interesting Observation of PDA Closure with Oral Paracetamol in Preterm Neonates. J Clin Neonatol. 2013; 2(1): 30-2.

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Pajouhan Scientific Journal

Designed & Developed by : Yektaweb